WILMINGTON, Del.--(BUSINESS WIRE)--Alexion, AstraZeneca Rare Disease, today announced the completion of its acquisition of LogicBio® Therapeutics, Inc. (NASDAQ: LOGC), a pioneering genomic medicine company.
Alexion, AstraZeneca Rare Disease, Completes Acquisition of LogicBio® Therapeutics
LogicBio Therapeutics Reports Third Quarter 2022 Financial Results and Provides Business Updates
LEXINGTON, Mass., Oct. 3, 2022 /PRNewswire/ -- LogicBio® Therapeutics, Inc. (NASDAQ: LOGC), a pioneering clinical-stage genomic medicine company, today announced that it has entered into a definitive agreement under which AstraZeneca Rare Disease will acquire LogicBio. The proposed acquisition brings LogicBio's unique technology, experienced rare disease R&D team, and expertise in pre-clinical development to support Alexion's growth in genomic medicines.
LEXINGTON, Mass., Sept. 21, 2022 /PRNewswire/ -- LogicBio Therapeutics, Inc. (Nasdaq: LOGC), a clinical-stage genetic medicine company, today announced that results from the company’s preclinical research study entitled “Novel AAV-mediated genome editing therapy prevents metabolic decompensation in a mouse model of methylmalonic acidemia” have been published in the peer-reviewed journal PLOS ONE.
LogicBio® Therapeutics, Inc. (NASDAQ: LOGC), a clinical-stage genetic medicine company, today reported financial results for the second quarter ended ...
LogicBio® Therapeutics, Inc. (NASDAQ: LOGC), a clinical-stage company advancing a diversified pipeline of genetic medicines addressing rare disorders ...
Shares of the Lexington, Massachusetts-based biotech were sent skyward by 60% as the markets opened Monday morning on the news that the phase 1/2 SUNRISE trial will get underway again. Even with that rapid climb, the shares are only worth 79 cents apiece, but the rally was much needed after the hold put a cash-strapped LogicBio in a tough position.
LogicBio Therapeutics’ bid to develop a genome editing therapy in infants has hit more trouble. Months after the first infant to receive the therapy suffered a serious adverse event, LogicBio has revealed the second subject has experienced the same clinical syndrome, prompting the FDA to impose a clinical hold.